Drug profile · INN
casirivimab
RONAPREVE
casirivimab (RONAPREVE) is a spike glycoprotein inhibitor.
EMA: withdrawn Antiinfectives for systemic use (J06) J06BD07
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — casirivimab
- Class
- Antiinfectives for systemic use (J06)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
casirivimab (RONAPREVE) is a spike glycoprotein inhibitor.
Key facts
INN casirivimab
Brand RONAPREVE
Mechanism Spike glycoprotein inhibitor
Target Spike glycoprotein
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BD07
Mechanism of action
Spike glycoprotein inhibitor
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is casirivimab?
casirivimab (RONAPREVE) is a spike glycoprotein inhibitor.
What is the brand name for casirivimab?
RONAPREVE is a marketed brand name for casirivimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.